Journal Scans
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Thalidomide Plus Standard Therapy Benefits Elderly MM Patients
P Wijermans, M Schaafsma, F Termorshuizen, R Ammerlaan, S Wittebol, H Sinnige, S Zweegman, M van Marwijk Kooy, R van der Griend, H Lokhorst, P Sonneveld
20100501
2010 Jun 1
J Clin Oncol
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
J Clin Oncol. 2010 Jun 1;[Epub Ahead of Print], P Wijermans, M Schaafsma, F Termorshuizen, R Ammerlaan, S Wittebol, H Sinnige, S Zweegman, M van Marwijk Kooy, R van der Griend, H Lokhorst, P Sonneveld
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Melphalan plus prednisone (MP) has long been the standard of care for elderly patients with multiple myeloma. Three recently published phase III trials have reported improved survival with the addition of thalidomide to standard MP in such patients. Wijermans et al report the results of a fourth trial, conducted by the Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). The open-label, multicenter, phase III randomized HOVON study compared MP with MP plus thalidomide (MP-T) in patients >65 years...
